Question special

As we are nearing the end of our forum, I thought it would be nice to shift gears a bit by taking a step back and talking about the impact IMPROVE-IT might have on the pharmaceutical landscape.

How exactly will such a study impact the marketing of Vytorin? What do you anticipate competing pharmaceutical companies responding?